Technical Analysis for LIXT - Lixte Biotech Hldgs
ADX | Long Term | Intermediate Term | Short Term |
---|---|---|---|
Strong | Down | Down | Down |
See historical LIXT trend table... |
Date | Alert Name | Type | % Chg |
---|---|---|---|
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Narrow Range Bar | Range Contraction | 0.00% | |
Inside Day | Range Contraction | 0.00% | |
Wide Bands | Range Expansion | 0.00% | |
200 DMA Resistance | Bearish | 0.00% | |
1,2,3 Retracement Bearish | Bearish Swing Setup | 0.00% | |
Non-ADX 1,2,3,4 Bearish | Bearish Swing Setup | 0.00% | |
Pocket Pivot | Bullish Swing Setup | 0.00% | |
Volume Surge | Other | 0.00% |
Get a Trading Assistant
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Sector: Healthcare
- Industry: Biotechnology
Lixte Biotechnology Holdings, Inc., including its subsidiary, Lixte Biotechnology, Inc., is a drug discovery company that uses biomarker technology to identify enzyme targets associated with serious common diseases and then designs compounds to attack those targets. The Company's primary focus is developing new treatments for human cancers. The Company designs drugs for which there are existing data suggesting that they may affect the altered pathways of the cancer cell and may be given safely to humans. This approach has led to the development of over two classes of drugs for the treatment of cancer, consisting of protein phosphatase inhibitors (PTase-i), designated by the Company as the LB-100 series of compounds, and histone deacetylase inhibitors (HDACi), designated by the Company as the LB-200 series of compounds. Compounds of both types also have use in the prevention and treatment of neurodegenerative diseases.
Branches Of Biology Cancer Health Sciences Treatment Of Cancer Drug Discovery Pharmaceutical Sciences Antineoplastic Drugs Neurodegenerative Diseases Histone Deacetylase
Branches Of Biology Cancer Health Sciences Treatment Of Cancer Drug Discovery Pharmaceutical Sciences Antineoplastic Drugs Neurodegenerative Diseases Histone Deacetylase
Indicator | Bull Case | Neutral / Hold | Bear Case |
---|---|---|---|
50 DMA | |||
200 DMA | |||
ADX Trend | |||
Oversold / Overbought | |||
Relative Strength |
Indicator | Value |
---|---|
52 Week High | 1.84 |
52 Week Low | 0.22 |
Average Volume | 3,407 |
200-Day Moving Average | 0.9876 |
50-Day Moving Average | 1.1349 |
20-Day Moving Average | 1.0565 |
10-Day Moving Average | 0.9604 |
Average True Range | 0.0930 |
ADX | 35.3 |
+DI | 18.7668 |
-DI | 40.2937 |
Chandelier Exit (Long, 3 ATRs ) | 1.0110 |
Chandelier Exit (Short, 3 ATRs ) | 1.0690 |
Upper Bollinger Band | 1.2857 |
Lower Bollinger Band | 0.8273 |
Percent B (%b) | 0.27 |
BandWidth | 43.3885 |
MACD Line | -0.0648 |
MACD Signal Line | -0.0513 |
MACD Histogram | -0.0135 |
Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
---|---|---|---|---|---|
Resistance 4 (R4) | 0.9500 | ||||
Resistance 3 (R3) | 0.9500 | 0.9500 | 0.9500 | ||
Resistance 2 (R2) | 0.9500 | 0.9500 | 0.9500 | 0.9500 | |
Resistance 1 (R1) | 0.9500 | 0.9500 | 0.9500 | 0.9500 | 0.9500 |
Pivot Point | 0.9500 | 0.9500 | 0.9500 | 0.9500 | 0.9500 |
Support 1 (S1) | 0.9500 | 0.9500 | 0.9500 | 0.9500 | 0.9500 |
Support 2 (S2) | 0.9500 | 0.9500 | 0.9500 | 0.9500 | |
Support 3 (S3) | 0.9500 | 0.9500 | 0.9500 | ||
Support 4 (S4) | 0.9500 |